SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
19692382
Source:
http://linkedlifedata.com/resource/pubmed/id/19692382
Search
Subject
(
60
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0010592
,
umls-concept:C0012634
,
umls-concept:C0025344
,
umls-concept:C0087111
,
umls-concept:C0205265
,
umls-concept:C0666743
,
umls-concept:C1555582
,
umls-concept:C1561960
,
umls-concept:C1707455
,
umls-concept:C1948053
,
umls-concept:C2347804
pubmed:issue
3
pubmed:dateCreated
2010-3-10
pubmed:abstractText
To compare the efficacy and safety of infliximab versus ciclosporin A (CsA) in refractory uveoretinitis in Behçet disease.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19692382-20215370
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/0421041
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal
,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine
,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents
,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1468-2079
pubmed:author
pubmed-author:KamoiKojuK
,
pubmed-author:KawaguchiTatsushiT
,
pubmed-author:MochizukiManabuM
,
pubmed-author:SugitaSunaoS
,
pubmed-author:TanakaHiroyukiH
,
pubmed-author:YamadaYukikoY
pubmed:issnType
Electronic
pubmed:volume
94
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
284-8
pubmed:meshHeading
pubmed-meshheading:19692382-Acute Disease
,
pubmed-meshheading:19692382-Adult
,
pubmed-meshheading:19692382-Antibodies, Monoclonal
,
pubmed-meshheading:19692382-Behcet Syndrome
,
pubmed-meshheading:19692382-Cyclosporine
,
pubmed-meshheading:19692382-Drug Evaluation
,
pubmed-meshheading:19692382-Female
,
pubmed-meshheading:19692382-Humans
,
pubmed-meshheading:19692382-Immunosuppressive Agents
,
pubmed-meshheading:19692382-Male
,
pubmed-meshheading:19692382-Middle Aged
,
pubmed-meshheading:19692382-Recurrence
,
pubmed-meshheading:19692382-Retrospective Studies
,
pubmed-meshheading:19692382-Treatment Outcome
,
pubmed-meshheading:19692382-Tumor Necrosis Factor-alpha
,
pubmed-meshheading:19692382-Uveitis
,
pubmed-meshheading:19692382-Visual Acuity
pubmed:year
2010
pubmed:articleTitle
Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
pubmed:affiliation
Department of Ophthalmology & Visual Science, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
pubmed:publicationType
Journal Article
,
Comparative Study